Navigation Links
OrthoAccel Technologies, Inc. Announces New Scientific Advisor

HOUSTON, Feb. 23, 2011 /PRNewswire/ -- OrthoAccel Technologies, Inc. developers of the AcceleDent System, a medical device to accelerate orthodontic treatment, announced this week that it has engaged Dr. Dawei Liu as a scientific advisor. Dr. Liu's guidance and expertise will help advance the Company's commitment to a research-focused strategy for developing and introducing innovative new products.  

AcceleDent is a simple, removable dental appliance that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement.  A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety and clinical utility of the device. The first completed AcceleDent case in private practice was documented last November in the United Kingdom. Dr. Liu's background is particularly relevant to OrthoAccel's focus. His extensive research has centered around the investigation of the effects of mechanical vibration on orthodontic tooth movement, in an attempt to shorten the total treatment time and reduce the risk of root resorption in clinical orthodontic patients.  Previously, he accepted an invitation from Dr. Birte Melsen to work as a Clinical Assistant Professor at the Department of Orthodontics at the Royal Dental College in Denmark.  Currently, he is the pre-doctoral Program Director and Research Director at Marquette University in the Department of Developmental Sciences / Orthodontics.

Michael Lowe, CEO of OrthoAccel, commented, "At OrthoAccel, we are always looking for ways to improve our technologies, and to provide the most scientifically advanced products to our customers.  Dr. Liu's scientific research complements OrthoAccel's objectives.  We believe that he can effectively guide us toward establishing an evidence-based foundation, which is an important objective." Dr. Liu remarked, "AcceleDent has the potential to revolutionize orthodontics and I am looking forward to working with Management to help guide OrthoAccel's future scientific research strategy."

OrthoAccel's Management team is traveling to Europe next month to work on commercialization efforts in several key markets.  

OrthoAccel has completed a pivotal US clinical trial at the UT Health Science Center in San Antonio, and is planning a submission for FDA clearance on AcceleDent later this month.   

About OrthoAccel Technologies, Inc.

Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.  

About the AcceleDent System

AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology.  The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling.  Importantly, the device works complementary with all existing orthodontic technologies.  AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States.  More information can be found at or requested via

SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
2. OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology
3. OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces
4. OrthoAccel Technologies, Inc. Announces Definitive Distribution Agreements in Two Key Markets
5. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
6. Patient Safety Technologies, Inc. to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference
7. Nopras Technologies, Inc. Achieves ISO 9001:2008 Certification
8. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
9. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
10. Reportlinker Adds Proteomics - Technologies, Markets and Companies
11. The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):